Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 2/20 | 0.53 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.53 |
| ▸ | AKR1C1 | Q04828 | 2/20 | 0.53 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.52 |
| ▸ | GLA | P06280 | 1/20 | 0.52 |
| ▸ | CASP7 | P55210 | 2/20 | 0.48 |
| ▸ | G6PD | P11413 | 1/20 | 0.48 |
| ▸ | CASP6 | P55212 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.44 |
| ▸ | CASP1 | P29466 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL2959725 | 0.98 | AKR1C3 (0.52) | AKR1C3AKR1C2AKR1C1AKR1C4KDM4E | |
| SCHEMBL13362844 | 0.83 | MAPT (0.45) | AKR1C3AKR1C2AKR1C1AKR1C4KDM4E | |
| SCHEMBL30505691 | 0.81 | KDM4E (0.59) | AKR1C3AKR1C2AKR1C1AKR1C4KDM4E | |
| SCHEMBL951441 | 0.81 | AKR1C3 (0.61) | AKR1C3AKR1C2AKR1C1AKR1C4KDM4E | |
| SCHEMBL30690387 | 0.81 | AKR1C3 (0.61) | AKR1C3AKR1C2AKR1C1AKR1C4KDM4E | |
| SCHEMBL11798181 | 0.81 | KDM4E (0.59) | AKR1C3AKR1C2AKR1C1AKR1C4KDM4E | |
| Hydrochloric Acid SCHEMBL11624392 | 0.79 | AKR1C3 (0.59) | AKR1C3AKR1C2AKR1C1AKR1C4KDM4E | |
| SCHEMBL31068478 | 0.78 | AKR1C3 (0.69) | AKR1C3AKR1C2AKR1C1AKR1C4KDM4E | |
| SCHEMBL12640756 | 0.78 | KDM4E (0.57) | KDM4ECASP7G6PDCASP6MAPT | |
| SCHEMBL8285504 | 0.78 | AKR1C3 (0.69) | AKR1C3AKR1C2AKR1C1AKR1C4KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9732066-B2 | Heterocyclic derivative and pharmaceutical drug | NIPPON SHINY AKU CO., LTD. (JP) | 2017-08-15 | — | — | US | disclosed |
| US-20160046612-A1 | Heterocyclic Derivative and Pharmaceutical Drug | NIPPON SHINYAKU CO., LTD. (JP) | 2016-02-18 | — | — | US | disclosed |
| US-9216968-B2 | Heterocyclic derivative and pharmaceutical drug | NIPPON SHINYAKU CO., LTD. (JP) | 2015-12-22 | — | — | US | disclosed |
| EP-2746265-B1 | HETEROCYCLIC DERIVATIVE AS MICROSOMAL PROSTAGLANDIN E SYNTHASE (mPGEs) INHIBITOR | NIPPON SHINYAKU CO LTD (JP) | 2015-11-18 | — | — | EP | disclosed |
| US-20140221339-A1 | Heterocyclic Derivative and Pharmaceutical Drug | NIPPON SHINYAKU CO., LTD. (JP) | 2014-08-07 | — | — | US | disclosed |
| EP-2746265-A1 | HETEROCYCLIC DERIVATIVE AND PHARMACEUTICAL DRUG | Nippon Shinyaku Co., Ltd. (JP) | 2014-06-25 | — | — | EP | disclosed |
| US-7781430-B2 | Benzoxazole carboxamides for treating CINV and IBS-D | ALBANY MOLECULAR RESEARCH, INC. (US) | 2010-08-24 | — | — | US | disclosed |
| US-7737166-B2 | Antifungal bicyclic hetero ring compounds | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-06-15 | — | — | US | disclosed |
| US-20090143353-A1 | such as 2-tert-Butyl-7-[(3S)-3-(dimethylamino)pyrrolidin-1-yl]-5-methyl-6-phenyl-1,3-benzoxazole-4-carbonitrile hydrochloride, a 1,6-beta-glucan synthetase inhibitor having potent growth inhibition, used treating a fungal infections; fungicides | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-06-04 | — | — | US | disclosed |
| EP-1932837-A1 | BICYCLO HETEROCYCLIC COMPOUND HAVING ANTIFUNGAL ACTION | Daiichi Sankyo Company, Limited (JP) | 2008-06-18 | — | — | EP | disclosed |
| US-20080108609-A1 | Benzoxazole Carboxamides For Treating CINV and IBS-D | AMR TECHNOLOGY, INC. (US) | 2008-05-08 | — | — | US | disclosed |
| CN-101160307-A | Benzoxazole carboxamides for the treatment of CINV and IBS-D | AMR TECHNOLOGY INC (US) | 2008-04-09 | — | — | CN | disclosed |
| US-7307094-B2 | Benzoxazole carboxamides for treating CINV and IBS-D | AMR TECHNOLOGY, INC. (US) | 2007-12-11 | — | — | US | disclosed |
| EP-1853597-A1 | BENZOXAZOLE CARBOXAMIDES FOR TREATING CINV AND IBS-D | AMR Technology, Inc. (US) | 2007-11-14 | — | — | EP | disclosed |
| WO-2006089100-A1 | BENZOXAZOLE CARBOXAMIDES FOR TREATING CINV AND IBS-D | AMR TECHNOLOGY, INC. (US) | 2006-08-24 | — | — | WO | disclosed |
| US-20060183769-A1 | Benzoxazole carboxamides for treating CINV and IBS-D | AMR TECHNOLOGY, INC. (US) | 2006-08-17 | — | — | US | disclosed |
| EP-0643686-A1 | NEW COMPOUNDS | Astra Aktiebolag (SE) | 1995-03-22 | — | — | EP | disclosed |
| CN-1076439-A | The new derivative of 3-hydroxyanthranilic acid, Preparation Method And The Use | ASTRA AB (SE) | 1993-09-22 | — | — | CN | disclosed |
| WO-1993005012-A1 | NEW COMPOUNDS | AB ASTRA (SE) | 1993-03-18 | — | — | WO | disclosed |
| EP-0530166-A2 | 3-Hydroxy anthranilic acid derivatives for inhibiting 3-hydroxy anthranilate oxygenase | Astra Aktiebolag (SE) | 1993-03-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143353-A1 | such as 2-tert-Butyl-7-[(3S)-3-(dimethylamino)pyrrolidin-1-yl]-5-methyl-6-phenyl-1,3-benzoxazole-4-carbonitrile hydrochloride, a 1,6-beta-glucan synthetase inhibitor having potent growth inhibition, used treating a fungal infections; fungicides | CTPS1, TPP1, STS | AKR1C3 2347/4885AKR1C2 2335/4885AKR1C1 1808/4885 |
| US-20140221339-A1 | Heterocyclic Derivative and Pharmaceutical Drug | PTGES, PTGER1, PTGS1 | AKR1C3 528/4885AKR1C2 452/4885AKR1C1 273/4885 |
| US-20080108609-A1 | Benzoxazole Carboxamides For Treating CINV and IBS-D | HTR3E, BRS3, HTR3A | AKR1C3 2713/4885AKR1C2 3304/4885AKR1C1 3360/4885 |
| US-20160046612-A1 | Heterocyclic Derivative and Pharmaceutical Drug | PTGES, PTGER1, PTGS1 | AKR1C3 528/4885AKR1C2 452/4885AKR1C1 273/4885 |
| US-20060183769-A1 | Benzoxazole carboxamides for treating CINV and IBS-D | HTR3E, BRS3, HTR3A | AKR1C3 2713/4885AKR1C2 3304/4885AKR1C1 3360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.